Human non-muscle Myosin IIA peptide (ab99161)

製品の概要

  • 製品名Human non-muscle Myosin IIA peptide

製品の詳細

  • 由来Synthetic

関連製品

特性

Our Abpromise guarantee covers the use of ab99161 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • アプリケーション

    Blocking - Blocking peptide for Anti-non-muscle Myosin IIA antibody (ab89837)

  • 精製度70 - 90% by HPLC.

  • 製品の状態Liquid
  • 備考

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

関連情報

  • 別名
    • BDPLT 6
    • BDPLT6
    • Cellular myosin heavy chain
    • Cellular myosin heavy chain type A
    • DFNA 17
    • DFNA17
    • EPSTS
    • FTNS
    • MGC104539
    • MHA
    • MYH 2A
    • MYH 9
    • MYH2A
    • MYH9
    • MYH9_HUMAN
    • MYHas8
    • MyHC 2A
    • MyHC IIa
    • MyHC2A
    • MyHCIIa
    • MYHSA 2
    • MYHSA2
    • Myosin 9
    • Myosin heavy chain
    • Myosin heavy chain 9
    • Myosin heavy chain 9 non muscle
    • Myosin heavy chain non muscle IIa
    • Myosin heavy chain nonmuscle IIa
    • Myosin heavy polypeptide 2
    • Myosin heavy polypeptide 9 non muscle
    • Myosin-9
    • Myosin9
    • NMHC II A
    • NMMHC A
    • NMMHC II a
    • NMMHC II-a
    • NMMHC IIA
    • NMMHC-A
    • NMMHC-IIA
    • NMMHCA
    • Non muscle myosin heavy chain
    • Non muscle myosin heavy chain A
    • Non muscle myosin heavy chain II A
    • Non muscle myosin heavy polypeptide 9
    • non-muscle IIa
    • Non-muscle myosin heavy chain A
    • Non-muscle myosin heavy chain IIa
    • Nonmuscle myosin heavy chain A
    • Nonmuscle myosin heavy chain II A
    • type A
    see all
  • 機能Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.
  • 組織特異性In the kidney, expressed in the glomeruli. Also expressed in leukocytes.
  • 関連疾患Defects in MYH9 are the cause of May-Hegglin anomaly (MHA) [MIM:155100]. MHA is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukokyte inclusions appearing as highly parallel paracrystalline bodies.
    Defects in MYH9 are the cause of Sebastian syndrome (SBS) [MIM:605249]. SBS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are smaller and less organized than in May-Hegglin anomaly.
    Defects in MYH9 are the cause of Fechtner syndrome (FTNS) [MIM:153640]. FTNS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are small and poorly organized. Additionally, FTNS is distinguished by Alport-like clinical features of sensorineural deafness, cataracts and nephritis.
    Defects in MYH9 are the cause of Alport syndrome with macrothrombocytopenia (APSM) [MIM:153650]. APSM is an autosomal dominant disorder characterized by the association of ocular lesions, sensorineural hearing loss and nephritis (Alport syndrome) with platelet defects.
    Defects in MYH9 are the cause of Epstein syndrome (EPS) [MIM:153650]. EPS is an autosomal dominant disorder characterized by the association of macrothrombocytopathy, sensorineural hearing loss and nephritis.
    Defects in MYH9 are the cause of deafness autosomal dominant type 17 (DFNA17) [MIM:603622]. DFNA17 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA17 is characterized by progressive hearing impairment and cochleosaccular degeneration.
    Defects in MYH9 are the cause of macrothrombocytopenia with progressive sensorineural deafness (MPSD) [MIM:600208]. MPSD is an autosomal dominant disorder characterized by the association of macrothrombocytopathy and progressive sensorineural hearing loss without renal dysfunction.
    Note=Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures.
    Note=Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD).
  • 配列類似性Contains 1 IQ domain.
    Contains 1 myosin head-like domain.
  • ドメインThe rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils.
  • 翻訳後修飾ISGylated.
  • Information by UniProt

Human non-muscle Myosin IIA peptide (ab99161) 使用論文

ab99161 has not yet been referenced specifically in any publications.

Product Wall

ab99161 is the blocking peptide for ab89837 and is therefore not a full length protein.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"